Compare Monster Beverage Corp (MNST) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs Zoetis Inc — how do they compare? Monster Beverage Corp trades at $43.02 (market cap $84.53B), while Zoetis Inc trades at $73.65 (market cap $30.40B). The key difference: Monster Beverage Corp is far larger — about 2.8× Zoetis Inc's market cap, and Zoetis Inc pays a 2.88% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals.
| MNST | ZTS | |
|---|---|---|
Market Cap | $84.53B | $30.40B |
Sector | Consumer Staples | Health |
52-Week High | $49.97 | $150.61 |
52-Week Low | $31.41 | $71.91 |
Enterprise Value | $82.83B | $37.96B |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $43.15, down 1.53% on the day, following a recent 2-for-1 stock split completed in August 2026. The stock exhibits a bullish technical signal from oscillators despite bearish moving averages, with key support at $42. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with $0.30 EPS, and shows robust revenue growth, with 2025 revenue reaching $8.29 billion and net income of $1.91 billion. Profitability remains high, with a net margin of 23.08% and ROE of 25.7%.
The outlook for MNST is positive, driven by consistent earnings beats, international expansion accounting for 46% of sales, and analyst consensus favoring a buy rating with a $51.10 price target. Key risks include elevated valuation multiples, such as a P/E of 39.95, and competitive pressures in the energy drink sector. Investors should weigh growth prospects against premium pricing.
Zoetis (ZTS) trades at $73.60, down 2.92% amid bearish technical signals and mixed earnings. The stock faces pressure from weakening U.S. companion animal sales and competitive headwinds, though profitability remains strong with 71.67% gross margins and 27.69% net income margin. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a guidance cut. Analyst consensus is divided with 45% Buy ratings and a $93.40 price target, suggesting 27% upside from current levels.
The outlook balances valuation appeal (P/E of 12) against near-term operational challenges. Investment opportunity lies in market dominance and robust cash flow generation, while risks include sustained pet health demand softness and competitive pricing pressure. The stock trades near support at $73, with institutional sentiment mixed amid recent portfolio adjustments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
